Add to ORKGThe Author(s) 2014. This article is published with open access at Springerlink.com The individualized treatment of type 2 diabetes mellitus, using various glucagon-like peptide receptor agonists (GLP1RAs), has recently been described. As experience with existing GLP1RAs grows, and as newer molecules in the development pipeline continue to progress, interest related to these drugs continues to grow. This article describes a person-centered approach, using the bio-psychosocial model of health, to help individualized decision making related to choice of GLP1RA. It utilizes an evidence-based approach to discuss various biomedical and psychosocial factors which may influence choice of GLP1RA
Type 2 diabetes (T2DM) is a chronic medical condition affecting millions of individuals worldwide. T...
Type 2 diabetes mellitus (T2DM) is a progressive disease accompanied by a gradual worsening of β-cel...
Introduction: Glucagon-like peptide-1 (GLP-1) is produced by the gut, stimulates insulin secretion f...
The Author(s) 2014. This article is published with open access at Springerlink.com Introduction: The...
BACKGROUND: It is estimated that 29.1 million people or 9.3% of the US population have diabetes, whi...
The article discusses the potential opportunities for impact of antidiabetic drugs from the group of...
In recent years, glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become central in the tre...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
Vivian T Thieu,1 Susan Robinson,2 Tessa Kennedy-Martin,2 Kristina S Boye,1 Luis-Emilio Garcia-Perez1...
Philip A Levin,1 Hiep Nguyen,2 Eric T Wittbrodt,2 Seoyoung C Kim3 1Bay West Endocrinology Associates...
Copyright © 2015 Feng Sun et al.This is an open access article distributed under the Creative Common...
In recent years the incretin therapies have provided a new treatment option for patients with type 2...
The prevalence of type 2 diabetes (T2D) is increasing worldwide. Patients with T2D suffer from vario...
Introduction: Glucagon-like peptide analogues are a new class of drugs used in the treatment of type...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
Type 2 diabetes (T2DM) is a chronic medical condition affecting millions of individuals worldwide. T...
Type 2 diabetes mellitus (T2DM) is a progressive disease accompanied by a gradual worsening of β-cel...
Introduction: Glucagon-like peptide-1 (GLP-1) is produced by the gut, stimulates insulin secretion f...
The Author(s) 2014. This article is published with open access at Springerlink.com Introduction: The...
BACKGROUND: It is estimated that 29.1 million people or 9.3% of the US population have diabetes, whi...
The article discusses the potential opportunities for impact of antidiabetic drugs from the group of...
In recent years, glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become central in the tre...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
Vivian T Thieu,1 Susan Robinson,2 Tessa Kennedy-Martin,2 Kristina S Boye,1 Luis-Emilio Garcia-Perez1...
Philip A Levin,1 Hiep Nguyen,2 Eric T Wittbrodt,2 Seoyoung C Kim3 1Bay West Endocrinology Associates...
Copyright © 2015 Feng Sun et al.This is an open access article distributed under the Creative Common...
In recent years the incretin therapies have provided a new treatment option for patients with type 2...
The prevalence of type 2 diabetes (T2D) is increasing worldwide. Patients with T2D suffer from vario...
Introduction: Glucagon-like peptide analogues are a new class of drugs used in the treatment of type...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
Type 2 diabetes (T2DM) is a chronic medical condition affecting millions of individuals worldwide. T...
Type 2 diabetes mellitus (T2DM) is a progressive disease accompanied by a gradual worsening of β-cel...
Introduction: Glucagon-like peptide-1 (GLP-1) is produced by the gut, stimulates insulin secretion f...